1986年Hoofnagle等首次使用a-干扰素(IFNa)治疗慢性非甲非乙型肝炎(CHNANB),发现可使部分患者血清ALT下降肝组织病变明显减轻. 此后许多学者开展了对IFN-a治疗(HNANB)的研究,取得了较大进展.1989年Choo等首先用分子克隆技术鉴定出丙型肝炎病毒(HCV)基因序列以来,相继建立了搞HCV和HCV-RNA的检测方法,从而开始了对HCV的全面研究,为评价干扰 In 1986, for the first time, Hoofnagle et al used interferon-alpha (IFNa) in the treatment of chronic non-A, non-B hepatitis (CHNANB), and found that some patients had a significant reduction in the serum ALT decreased hepatic tissue lesions.After that many scholars conducted IFN- HNANB) has made great progress.In 1989, Choo and other first identified by molecular cloning of hepatitis C virus (HCV) gene sequence since the establishment of HCV and HCV-RNA detection methods, which started the right Comprehensive study of HCV, to evaluate interference